BioSpace News Archive

CarboFix has announced today that the U.S. Food and Drug Administration (FDA) has cleared its CarboClear® Carbon Fiber Vertebral Body Replacement (VBR) System to replace a collapsed, damaged, or unstable vertebral body due to tumor or trauma.

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced it intends to release its third quarter 2019 financial results before markets open on Thursday, October 31, 2019.

Emergency medical professionals can securely message and view patient medication histories at the scene to improve care continuity, quality, and safety

Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Mercy, one of the top five U.S. health systems that serves Arkansas, Kansas, Missouri and Oklahoma, will support medication management across its service network through Omnicell automation and intelligence solutions.

Today Inversago Pharma Inc., a preclinical-stage biotech company developing novel CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of two seasoned pharma executives in line with the Company’s aim to attract first-class industry leaders for their guidance and expertise.

NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab) biosimilar candidate, NeuLara, in a Phase I clinical trial.

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke.

Sensorion announced the last patient’s last visit in its Phase 2 clinical trial for SENS-111 investigated for the potential treatment of Acute Unilateral Vestibulopathy

Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease

Hutchison China MediTech Limited highlighted the publication of results from the Phase II VIKTORY trial in Cancer Discovery, a journal of the American Association of Cancer Research.